A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women (SHIFT)

This study has been withdrawn prior to enrollment.
(Change in company direction)
Sponsor:
Information provided by:
Zelos Therapeutics
ClinicalTrials.gov Identifier:
NCT00787358
First received: November 6, 2008
Last updated: June 3, 2009
Last verified: June 2009
  Purpose

The purpose of this research study is to test if an experimental drug called ZT-031 can help men over 30 years or post-menopausal women over 55 years of age with certain types of hip fracture to heal better or faster following surgery and to determine if ZT-031 is safe for patients with fractures. To be allowed in the study you have to have a type of hip fracture that requires surgery that is being studied (intertrochanteric fracture). You must also otherwise be in good health, with no serious diseases such as cancer, neurologic disease, other bone disease, liver, heart or kidney disease. You must be able to inject yourself every day with the study medication using an injection pen, like that used for insulin injections.


Condition Intervention Phase
Hip Fracture
Drug: ZT-031
Other: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo Controlled Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women With Intertrochanteric Fracture of the Hip

Resource links provided by NLM:


Further study details as provided by Zelos Therapeutics:

Primary Outcome Measures:
  • Compression hip screw (CHS) migration: the difference in the tip apex distance (TAD) post-operatively to that at Visit 7/Week 16 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Screw barrel impaction distance [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
  • Screw cut-out and/or other hardware failure [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
  • Incidence of fracture non-union [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
  • Need for surgical revision with or without hardware removal [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: December 2008
Estimated Study Completion Date: July 2009
Estimated Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: ZT-031 Drug: ZT-031
80 ul subcutaneous injection per day
Placebo Comparator: Placebo Other: placebo
80 ul daily subcutaneous injection of vehicle only

  Eligibility

Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Subjects are required to meet all of the following criteria for inclusion in the study:

  1. Signed Institutional Review Board (IRB)/Research Ethics Board (REB)-approved informed consent form (ICF).
  2. Sustained an unstable low energy intertrochanteric (Evans Type II or higher) hip fracture within 7 days prior to planned surgery date. Low energy is defined as a fracture that occurs spontaneously or from a fall from a stationary height of ≤ 1 meter (3 feet) or missing one to three steps.
  3. Women ≥ 55 years of age and men ≥ 30 years of age of any race. If female, subjects must be post-menopausal for at least 5 years and weigh ≥ 110 lbs or 50 kg.
  4. Subjects who are expected to undergo or have recently undergone (within two weeks) open or closed repair of the fracture requiring a CHS.
  5. By history, the subject was at least household ambulatory prior to hip fracture.
  6. Serum calcium level within the normal range when corrected for albumin. Corrected calcium (mg/dL) = Serum Ca (mg/dL) + 0.8 x (4.0 - albumin [g/dL])
  7. Able and willing to comply with all protocol procedures.
  8. Cognitive, visual, auditory and physical abilities adequate to undertake assessments.
  9. Availability of a care partner to administer injections or demonstrated ability to self-administer injections. Subjects planning to self-administer study drug will need to show that they will be capable of accurately self-injecting study drug in rotating quadrants of the abdomen, in the opinion of the Investigator.
  10. Clinically acceptable medical history and physical examination, according to the judgment of the Investigator.
  11. Laboratory results within normal ranges or, if abnormal, considered by the Investigator as not clinically significant for the well-being of the subject or for the purpose of the study.

    The following additional criteria are required for randomization and dosing with ZT-031 or placebo to occur:

  12. The most recent value for 25-hydroxy Vitamin D (25OHD) must be at or above the lower limit of normal (LLN) for the laboratory reference range of the testing method used for determination of 25OHD. NOTE: Randomization should be delayed until it is known that 25OHD is ≥ LLN.
  13. The most recent value for intact PTH must be ≤ ULN for the laboratory reference range.
  14. Randomization and dosing must occur within 2 weeks post-op. Exclusion Criteria

Subjects who meet any of the following conditions are excluded from this clinical study:

  1. Previous fracture(s) or bone or joint surgery in the currently fractured site
  2. Intertrochanteric fracture with reverse obliquity
  3. Pathologic fracture: A fracture occurring at a site of metabolic bone disease (other than osteoporosis) or a benign or malignant tumor
  4. Presence of a concurrent disease known to affect bone metabolism other than post-menopausal osteoporosis, including but not limited to hyperparathyroidism, hyperthyroidism, osteogenesis imperfecta, abnormalities of serum calcium, Paget's disease, or osteomalacia
  5. History of rheumatoid arthritis
  6. Any significant neurologic disease including but not limited to any dementing illness or other neurodegenerative disease, cerebrovascular disease, epilepsy or undiagnosed syncope
  7. Unstable or clinically significant cardiovascular disease resulting in:

    1. Hemodynamic instability manifested as hypotension unresponsive to intravenous fluids
    2. Uncontrolled hypertension requiring administration of parenteral therapy.
  8. Renal disease, defined by:

    1. Creatinine level of >2.0 mg/dL
    2. Urolithiasis or nephrolithiasis in the last 2 years
  9. Hepatic disease or insufficiency, defined by liver function tests (ALT, AST or GGT) > 3 times the ULN or bilirubin > 34 mmol/L or 2.0 mg/dL
  10. Currently receiving treatment for cancer
  11. History of external beam radiation to the skeleton or a radiation therapy implant device
  12. Presence of substance abuse, including alcohol, within 1 year of Screening
  13. Current or previous use of any PTH compound, including ZT-031
  14. Use of any investigational compound within 4 weeks of Screening, or within 5 half-lives of compound, whichever is longer
  15. Use of any bone substitutes, osteobiologics or any fracture healing drug.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00787358

Locations
United States, New York
J. Edward Puzas
Rochester, New York, United States, 14642
Sponsors and Collaborators
Zelos Therapeutics
  More Information

No publications provided

Responsible Party: Dr. David S. Krause, Chief Medical Officer, Zelos Therapeutics
ClinicalTrials.gov Identifier: NCT00787358     History of Changes
Other Study ID Numbers: OC-018
Study First Received: November 6, 2008
Last Updated: June 3, 2009
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Keywords provided by Zelos Therapeutics:
osteoporosis
intertrochanteric
hip fracture
compression hip screw
surgical fixation

Additional relevant MeSH terms:
Fractures, Bone
Hip Fractures
Wounds and Injuries
Femoral Fractures
Hip Injuries
Leg Injuries

ClinicalTrials.gov processed this record on August 28, 2014